Rare disease clinical trials have several challenges that make them more difficult to conduct than clinical trials for more common diseases. Small patient populations, pediatric populations and the desire by patients and their caregivers to receive active therapy while on a clinical trial make it much more likely that rare disease trials will be conducted without placebo control groups. An alternative to a placebo control group is the use of existing medical history information on a group of similar patients to provide a historical control.
Recent developments by regulatory agencies have resulted in increasing use of historical control groups to provide comparative evidence to establish the efficacy and safety of rare disease therapies. This webinar provides an overview of the use of historical control populations in rare disease drug development and approval.
Join this free webinar to learn about the challenges and opportunities of this approach, including:
- Sources for historical control information, including prospective and retrospective data
- The advantages and implications on study enrollment, study budget and time to market
- How to identify and address data consistency, quality and outcomes assessment methods
- The current regulatory landscape in the US and Europe and a review of recent approvals using historical controls
Speaker
William C. Maier, MPH, PhD, Chief Science Officer & Head, Rare Diseases Commercialisation and Outcomes, ICON
Dr. William Maier has over 30 years of experience with pharmaceutical companies in Europe, Canada, the US and Asia. At ICON, he works with pharmaceutical companies to provide regulatory, strategic and scientific guidance on medical treatment development and commercialisation. William is a member of the EMEA’s European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. He is a frequent speaker at medical conferences and is a member of the Royal Society of Medicine in the UK.
Message PresenterWho Should Attend?
This webinar will appeal to VPs, directors, managers, department heads, scientists and researchers working within:
- Clinical Affairs
- Clinical R&D
- Clinical Research
- Clinical Pharmacology
- Clinical Operations
- Project Management
- Regulatory Affairs
- Medical Affairs
What You Will Learn
Participants will gain insights into:
- Sources for historical control information, including prospective and retrospective data
- The advantages and implications on study enrollment, study budget and time to market
- How to identify and address data consistency, quality and outcomes assessment methods
- The current regulatory landscape in the US and Europe and a review of recent approvals using historical controls
Xtalks Partner
ICON
ICON plc is a global provider of outsourced development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specializes in the strategic development, management and analysis of programs that support clinical development. With headquarters in Dublin, Ireland, ICON currently operates from 97 locations in 38 countries and has approximately 13,380 employees. Further information is available at ICONplc.com.
Related Webinars
Streamlining IRT in clinical trials: Simplify, optimise, succeed
ICON’s World Children’s Day
Why outsourcing pharmacovigilance makes sense at an affiliate level
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account